Skip to content
ClinCalc Pro
Menu
Opioid Receptor Antagonist

Naltrexone

Brand names: Nalorex, Vivitrol (extended-release IM)

Naltrexone is a long-acting opioid antagonist used as an adjunct to maintain abstinence in formerly opioid-dependent people and in alcohol dependence.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It competitively blocks opioid receptors, abolishing the euphoric and other effects of exogenous opioids and modulating alcohol-related reward pathways.

Prescribing in practice

  • It can precipitate acute, severe opioid withdrawal in opioid-dependent patients, so the patient must be opioid-free for an adequate period (confirmed where appropriate) before starting.
  • Because it blocks opioid analgesia, plan alternative pain management and warn that attempts to override the block with large opioid doses risk fatal overdose, especially after treatment stops when tolerance is lost.
  • Assess liver function before and during treatment, as hepatotoxicity has been reported at higher doses.

Monitoring

Monitor liver function and adherence, and review ongoing abstinence and psychosocial support during treatment.

Counselling the patient

  • Carry information that you are taking an opioid blocker so emergency teams can plan pain relief.
  • Do not try to overcome the blockade with opioids, and remember your tolerance falls after stopping, raising overdose risk.

Evidence & guidelines

Naltrexone as part of a relapse-prevention programme is supported by NICE guidance on alcohol-use and opioid-dependence management.

Reference: COMBINE trial (Anton et al. JAMA 2006); NICE CG115 (Alcohol Use Disorders); NICE CG52 (Opioid Dependence); MHRA SPC Nalorex; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.